Skip to content

Study · Case report or series · n = 1 · 2024

2 results

Skeletal fluorosis: an uncommon cause, yet a rescue treatment?

Shariff JRR, Swe KM, Binkley N, Whyte MP, Pabich SK

Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA7 Jun 2024Cited by 2 (Europe PMC)

PMID38847810 (opens in a new tab)DOI10.1007/s00198-024-07137-x (opens in a new tab)PepBankPUB-38847810
Publisher pagePubMedAsk about this study
Jump to 2 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study2

2 results from studies that gave the peptide. 2 results from people.

  1. 01HumanCase report or seriesEfficacy outcome

    In a woman with skeletal fluorosis after fluoride exposure cessation, bone density decreased following abaloparatide treatment.

    In plain wordsIn a woman with skeletal fluorosis, bone density decreased after abaloparatide and cessation of fluoride exposure.

    Peptide
    Abaloparatide (Tymlos)
    Outcome
    DecreaseBone density
    Study

    n = 1

    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Following abaloparatide treatment for our patient, there was a decrease in bone density as well as a reduction in F- levels.
    2 context sentences
    Summary · context
    A 50-year-old woman presented with multiple, recurrent, low AQ2 trauma fractures yet high radiologic bone mineral density.
    Summary · context
    Following cessation of her F- exposure, we evaluated the administration of the parathyroid hormone analog, abaloparatide, hoping to increase bone remodeling and diminish her skeletal F- burden.
  2. 02HumanCase report or seriesEfficacy outcome

    In a woman with skeletal fluorosis after fluoride exposure cessation, fluoride levels decreased following abaloparatide treatment.

    In plain wordsIn a woman with skeletal fluorosis, fluoride levels decreased after abaloparatide and cessation of fluoride exposure.

    Peptide
    Abaloparatide (Tymlos)
    Outcome
    DecreaseFluoride levels
    Study

    n = 1

    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Following abaloparatide treatment for our patient, there was a decrease in bone density as well as a reduction in F- levels.
    2 context sentences
    Summary · context
    A 50-year-old woman presented with multiple, recurrent, low AQ2 trauma fractures yet high radiologic bone mineral density.
    Summary · context
    Following cessation of her F- exposure, we evaluated the administration of the parathyroid hormone analog, abaloparatide, hoping to increase bone remodeling and diminish her skeletal F- burden.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:25 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.